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Blood neutrophil counts are associated
with exacerbation frequency and mortality
in COPD
Mike Lonergan1†, Alison J. Dicker1†, Megan L. Crichton1, Holly R. Keir1, Melissa K. Van Dyke2, Hana Mullerova3,
Bruce E. Miller4, Ruth Tal-Singer4 and James D. Chalmers1*
Abstract
Background: Identifying patients with COPD at increased risk of poor outcomes is challenging due to disease
heterogeneity. Potential biomarkers need to be readily available in real-life clinical practice. Blood eosinophil counts
are widely studied but few studies have examined the prognostic value of blood neutrophil counts (BNC).
Methods: In a large population-based COPD registry in the East of Scotland (TARDIS: Tayside Allergic and Respiratory
Disease Information System), BNC were compared to measures of disease severity and mortality for up to 15 years
follow-up. Potential mechanisms of disease modification by BNC were explored in a nested microbiome substudy.
Results: 178,120 neutrophil counts were obtained from 7220 people (mean follow up 9 years) during stable disease
periods. Median BNC was 5200cells/μL (IQR 4000-7000cells/μL). Mortality rates among the 34% of patients with
elevated BNCs (defined as 6000-15000cells/μL) at the study start were 80% higher (14.0/100 person years v 7.8/100py,
P < 0.001) than those with BNC in the normal range (2000-6000cells/μL). People with elevated BNC were more likely to
be classified as GOLD D (46% v 33% P < 0.001), have more exacerbations (mean 2.3 v 1.3/year, P < 0.001), and were
more likely to have severe exacerbations (13% vs. 5%, P < 0.001) in the following year. Eosinophil counts were much
less predictive of these outcomes. In a sub-cohort (N = 276), patients with elevated BNC had increased relative
abundance of Proteobacteria and reduced microbiome diversity.
Conclusion: High BNC may provide a useful indicator of risk of exacerbations and mortality in COPD patients.
Keywords: COPD, Mortality, Eosinophil, Neutrophil, Microbiome
Background
Biomarkers are needed in Chronic Obstructive Pulmonary
Disease (COPD) for effective risk stratification and to guide
personalized treatment. Blood eosinophil counts have been
extensively investigated to stratify patients with COPD,
based on evidence that blood and sputum eosinophil counts
are linked, and both are associated with increased
exacerbation frequency, reduced lung function and respon-
siveness to inhaled corticosteroids (ICS) [1]. Only a minority
of COPD patients, however, exhibit eosinophilia; COPD is
predominantly characterized as a neutrophilic inflammatory
disorder [2, 3]; because the most abundant inflammatory cell
in blood and sputum is the neutrophil, and because neutro-
phil proteases can recapitulate many of the features of
COPD in disease models, such as emphysema and mucus
hypersecretion [4–6]. The introduction of blood eosinophil
counts into clinical practice recommendations from GOLD
illustrates the potential for simple clinical measures to come
into daily practice, but whether blood neutrophil counts
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(BNC) can be used to inform clinical decisions has not been
extensively investigated in large cohorts.
Increased peripheral neutrophil counts are a reflection
of systemic inflammation which is linked to disease se-
verity and co-morbidities in COPD. Correlations be-
tween disease severity stage and neutrophil activation
markers (e.g. neutrophil elastase (NE), myeloperoxidase
and neutrophil extracellular traps) in sputum and bron-
choalveolar lavage have been shown previously [7–9].
We therefore hypothesized that BNC would be a pre-
dictor of COPD severity, exacerbation and mortality.
Methods
Study design
Seven thousand two hundred twenty people with a
COPD diagnosis were identified within the TARDIS
(Tayside Allergy and Respiratory Disease Information
System) database. Details of TARDIS have been previ-
ously described and are detailed online [10]. In brief,
since 2008 patients age > 40 years, with a post-
bronchodilator FEV1/FVC ratio < 0.7 (70%) and a clinical
diagnosis of COPD were invited to participate in a struc-
tured primary care cohort. Patients were reviewed annu-
ally for spirometry, recording of symptoms and
exacerbation history. Patient’s TARDIS data was linked
to regional prescribing databases, and databases that rec-
ord hospitalizations and deaths nationally. The study
was approved by the local research ethics committee ap-
proval number 13/ES/0030.
Blood neutrophil counts
The index date for each participant was set as the date of
the first stable BNC recorded after they had been in the
TARDIS study for 12months. A stable BNC was one con-
sidered representative of times when that person’s COPD
was stable and unaffected by exacerbations or short-tern
medical treatment. BNCs made between 1 week before
and 4 weeks after the start of a COPD exacerbation, de-
fined as either receipt of a short course of prednisolone
(defined as an acute prescription for at least 30mg/day for
at least 5 days) or a respiratory hospitalization, were ex-
cluded as potentially being elevated by the immediate ef-
fects of the exacerbation or associated corticosteroid
treatment. The online supplementary material gives de-
tails of the derivation of each variable used.
Extremely low and extremely high BNCs can result
from various diseases and have the potential to dominate
analyses that dichotomize or treat effects as linear.
Therefore, the BNCs were split into four categories: low
(<2000cells/μL); normal (2000–6000cells/μL); elevated
(6000–15,000cells/μL); and extreme (> 15,000cells/μL).
The upper bound of the normal range for BNC has often
been taken to be 8000cells/μL in clinical practice so the
models were refitted using that cut-off point in a
sensitivity analysis. Models were also fitted, including all
individuals, with BNC as a linear term as a sensitivity
analysis. The primary interest was how people with ele-
vated BNC differed from those in the normal range.
Microbiome sub cohort
Two hundred seventy-three patients in the TARDIS co-
hort had been previously recruited into prospective lon-
gitudinal studies as previously described [10].
Participants were clinically assessed after giving written
informed consent (Relevant medical history, Spirometry,
St Georges Respiratory Questionnaire (SGRQ), GOLD
2017 scores, COPD Assessment Test (CAT), and Med-
ical Research Council (MRC) Dyspnoea Score), and spu-
tum and blood obtained when clinically stable at study
enrolment. Full blood counts and C-reactive protein
were measured at every visit. DNA was extracted from
the induced sputum obtained at visits and 16S rRNA
microbiome sequencing performed as detailed in the on-
line supplement. All sequences generated are available in
the NCBI Sequence Read Archive under the Bioproject
accession numbers PRJNA316126 and PRJNA539959.
Validation in ECLIPSE
BNCs were measured as a biomarker in the ECLIPSE co-
hort, a longitudinal COPD cohort study that has been
previously described [11]. The original study had a dur-
ation of 3 years. Patients who provided consent for add-
itional follow-up to 8 years were included and the
relationship between baseline BNCs and survival was ex-
amined after adjustment for confounders using Cox pro-
portional hazards regression.
Statistical analysis
Data were summarized by BNC group to give simple com-
parisons. Regression models were then used to look at
how other potential explanatory variables might change
the results. Cox proportional hazard models of all-cause
mortality were fitted, along with survival models of mor-
tality recorded as being due to ICD10 code J44 (COPD)
and ICD10 codes J00–99 (all respiratory mortality). The
models of disease specific mortality treated other causes
of mortality as competing risks. Generalized linear models
(GLMs), with log links and negative binomial errors, were
used to look at the frequency of severe exacerbations (de-
fined as hospitalization with the main condition recorded
as ICD10 code J44), and all acute exacerbations (defined
as respiratory hospitalization or receiving a course of
prednisolone), in the 12months from the index date.
To examine changes in stable FEV1, mixed models
were fitted. These contained an intercept and slope for
each BNC group as fixed effects, along with an intercept
and slope for each individual as random effects. Because
the mixed model assumes linear changes in FEV1, and
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there was high mortality in this cohort, a second set of
mixed models was fitted using only measurements taken
within 3 years of the index dates.
Unadjusted models were fitted, using the four BNC
levels to predict the outcomes, comparing the other
groups to the normal BNC group. The models were then
adjusted for age, sex and smoking status and refitted. To
examine the stability of the results, 35 further versions
of each model were fitted, each adjusting for another
plausible confounding variable as listed in e-Table 1.
Results
From the 7220 COPD patients in TARDIS, 178120
stable and 15,826 exacerbation associated BNCs were
obtained (Fig. 1); their clinical characteristics at index
are shown in Table 1. The median age of patients at
index was 75 years (interquartile range (IQR) 65–81),
48% were male, 4525 (63%) were ICS users and 3494
(49%) were current smokers whilst median FEV1 was
1.6 L (IQR 1.1–2.0). Comparing the normal and elevated
groups, the elevated group were older, more likely to be
smokers, receiving ICS, and had more exacerbations and
a lower index FEV1 (Table 1). 2% of stable BNCs were
classed as low; 50% as normal, 43% as elevated and 4%
as extreme. Less than 1% of the exacerbation BNCs were
classed as low; 38% as normal, 56% as elevated and 6%
extreme.
Blood eosinophil analysis
The association between index blood eosinophil counts
and mortality was weak and only evident in patients with
blood eosinophil counts <100cells/μL (Fig. 2a). No sig-
nificant difference in all-cause mortality, mortality due
to COPD or change in FEV1 was observed between the
different blood eosinophil count groups. The total ex-
acerbation rates were also indistinguishable, though the
rate of severe exacerbations was lower among those with
elevated index blood eosinophils than in all other groups
(e-Fig. 1 and e-Table 2).
Elevated BNCs and increased mortality
BNC were significantly higher during exacerbations (P <
0.001; Fig. 2b), though this difference was small com-
pared to the within-individual variability (median coeffi-
cient of variation 0.36; IQR 0.26–0.48; e-Figure 2).
Despite this variability, a pattern of mortality risk being
higher for those with BNC outside the normal range,
was evident. Unsurprisingly, the association of mortality
with index BNC (Fig. 2c) was less strong than that for
the final BNC (Fig. 2d). These patterns were similar for
all-cause mortality and that recorded as due to COPD.
The patterns in the raw data (Fig. 2c & d) remained as
statistically significant differences (P < 0.001) in survival
between the BNC groups even after adjustment for age,
sex and smoking history, with 10 year survival for those
with an elevated BNC being about 2/3 of that for those
with normal BNC at index (Fig. 3a and b). Very similar
results were obtained for unadjusted models, and those
considering all respiratory (ICD code J) deaths (e-Figure
3). The adjusted model with BNC as a linear term esti-
mated the hazard ratio for all-cause mortality at 1.067
(95%CI: 1.060–1.073 per 1000cells/μL), and that for
COPD mortality at 1.091 (95%CI: 1.082–1.100). These
estimates, while still significant, are lower than the be-
tween group differences (e-Table 3) because there is
high mortality among the group with low index BNC.
Additional models did not identify any important con-
founding effects (e-Figures 4 and 5).
The elevated BNC group had more exacerbations than
the normal BNC group in both the year before index
(mean 2.3 vs 1.3 exacerbations/year, P < 0.001) and the
year following index (1.9 vs 1.5, P < 0.001). The incident
rate ratios for all exacerbations or severe exacerbations
alone in the 12months following index date were
Fig. 1 Flow chart of numbers of patients and samples in TARDIS, and each set of analyses
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Table 1 Characteristics of the cohort at index date
All Normal index BNC Elevated
index BNC
Significance
n 7220 4465 (62%) 2462 (34%)
Age 75 (65, 81) 72 (64, 80) 74 (67, 82) P < 0.001
Male Gender 3470 (48%) 2149 (48%) 1171 (48%) P = 0.67
BMI 28 (24, 31) 28 (24, 31) 28 (23, 32) P = 0.63
ICS usea 4525 (63%) 2680 (60%) 1635 (66%) P < 0.001
LABA only 146 (2%) 101 (2%) 42 (2%) P = 0.14
LAMA only 555 (8%) 339 (8%) 196 (8%) P = 0.61
LABA & LAMA 168 (2%) 103 (2%) 58 (2%) P = 0.96
SABA 6068 (84%) 3672 (82%) 2137 (87%) P < 0.001
Current smokers 3494 (48%) 2104 (47%) 1264 (51%) P = 0.02
Ex-smokers 3300(46%) 2071 (46%) 1078 (44%)
Spirometry P < 0.001
FEV1 (Litres) 1.58 (1.11, 1.98) 1.64 (1.23, 1.91) 1.49 (1.00, 1.87)
GOLD 2017 P = 0.002
A 332 (8%) 243 (9%) 82 (6%)
B 2174 (51%) 1464 (54%) 646 (46%)
C 132 (3%) 99 (4%) 30 (2%)
D 1620 (38%) 888 (33%) 634 (46%)
Index total white cell count (cells/μL) 8300 (6900, 1030) 7300 (6300, 8300) 10,800 (9700, 12,600) P < 0.001
Index BNC (cells/μL) 5200 (4000, 7000) 4300 (3600, 5100) 7600 (6600, 9400) P < 0.001
Index eosinophil count (cells/μL) 180 (90, 290) 200 (120, 300) 150 (60, 280) P < 0.001
< 150 2960 (41%) 1518 (34%) 1206 (49%)
> 150; < 300 2521 (35%) 1765 (40%) 720 (30%)
> 300; < 500 1253 (17%) 869 (19%) 369 (15%)
> 500 486 (7%) 313 (7%) 167 (7%)
Exacerbation frequency (year to index date) P < 0.001
0 2679 (37%) 1797 (40%) 792 (32%)
1 1653 (23%) 1075 (24%) 535 (22%)
2 1033 (14%) 606 (14%) 380 (15%)
3 or more 1855 (26%) 987 (22%) 755 (31%)
Severe exacerbation (year to index date) 577 (8%) 162 (4%) 334 (14%)
Exacerbation frequency (year from index date) P < 0.001
0 2989 (41%) 1870 (42%) 988 (40%)
1 1549 (21%) 1019 (23%) 493 (20%)
2 1005 (14%) 649 (15%) 329 (13%)
3 or more 1677 (23%) 927 (21%) 652 (26%)
Severe exacerbation (year from index date) 633 (9%) 245 (5%) 322 (13%)
Crude mortality rate
(per 100 person-years)
10.0 7.9 14.0 P < 0.001
Abbreviations: BNC Blood Neutrophil Count, ICS Inhaled corticosteroids, BMI Body mass index, MRC Medical Research Council, FEV1 Forced expiratory volume in 1 s,
FVC Forced vital capacity, aincludes medication used in combination with other bronchodilators or inhaled steroids. Each cell contains the median (IQR) or n (%).
Not every measurement is available for every individual at the index visit hence not all percentages add up to 100%. T-tests were used to estimate the
significance of differences between the characteristics of the groups, except for categorical variables where Chi-squared tests were used and ones where the
distributions within either group failed the Shapiro-Wilks test of normality and the Mann-Whitney test was used instead. The large sample size made some small
differences statistically significant.
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determined, with the normal BNC group as reference;
two models are shown (Fig. 3c), one unadjusted and the
second adjusted for age, sex and smoking history. The
adjusted models indicated that, for patients with an ele-
vated BNC, there was a 40% increase in total exacerba-
tions, and a 170% increase in severe exacerbations in the
year from index relative to the rates for those with nor-
mal BNC (P < 0.001 in both cases). The adjusted model
with BNC as a linear term, estimated that each increase
of 1000cells/μL in BNC was associated with the total ex-
acerbation rate increasing by a factor of 1.05 (95%CI:
1.04–1.06). For severe exacerbations, the figure was 1.17
(95%CI: 1.14–1.20). In the year from index date the
much smaller group of patients with an extreme BNC
had an increase in all and severe exacerbations of 96 and
450% (P < 0.001 in both cases; e-Figure 6).
Additional GLMs did not identify any important con-
founding effects (e-Figures 7 and 8). When looking at all
exacerbations, the neutrophil effect remained significant
in every case, with only the total number of
exacerbations in the year up to index date attenuating
the magnitude of the effect. (e-Figure 7). Restricting the
analysis to the younger half of the cohort did not change
the results (e-Figure 9). Changing the upper limit of the
normal range from 6000 to 8000cells/μL halved the size
of the elevated BNC group, and widened confidence in-
tervals, without changing the overall results or conclu-
sions (e-Figure 10).
The overall rate of change in FEV1, across the whole co-
hort was − 0.038 (95%CI: − 0.034, − 0.041) L/yr or 38mL/
yr. The rate within the elevated BNC group was indistin-
guishable from the normal BNC group (Fig. 3d). While es-
timated rate of decline for the elevated BNC group was
slightly faster (difference − 0.004; 95%CI: − 0.010, 0.003),
the difference was not statistically significant, and was re-
versed when consideration was restricted to only the first
3 years after the index date (difference between groups
0.002; 95%CI: − 0.012, 0.015). However, these confidence
intervals are too wide to entirely rule out the existence of
a clinically meaningful difference.
Fig. 2 a: The proportion of individuals recorded as having died at the end of follow up (black) plotted against their index blood eosinophil
count. The red symbols are proportions (out of all individuals) with death from a cause recorded as falling within ICD10 category J44 (COPD). b:
Distribution of blood neutrophil counts (BNCs) showing all values (hollow bars); all measurements from individuals with stable and exacerbating
results available (black bars) and measurements made during exacerbations (red bars). The black dots show the proportion of BNCs made outside
of exacerbation periods. Three vertical dotted lines indicate the cut-offs applied to separate BNCs into normal (<6000cells/μL), elevated (6000–
15,000cells/μL) and extreme (> 15,000cells/μL) c: The proportion of individuals recorded as having died by the end of follow up (black) plotted
against their index BNC. The red symbols are proportions (out of all individuals) with death from a cause recorded as falling within ICD10
category J44. Three vertical dotted lines indicate the cut-offs applied to separate BNCs into low (<2000cells/μL), normal (2000–6000cells/μL) and
elevated 6000–15,000cells/μL) d: as C, but using the last BNC recorded for each individual. Solid points are based on final stable BNC, while
hollow ones include BNC recorded during exacerbations
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Microbiome sub-cohort
Two hundred seventy-three patients provided at least
one sputum sample, when clinically stable, of which 246
samples passed sequencing quality control to be in-
cluded in the analysis. Utilizing the same cut offs as the
main TARDIS cohort, 1 patient had a low BNC, 159
were normal, 79 elevated and 7 extreme. For the pur-
pose of the microbiome analysis, low and normal pa-
tients were grouped as <6000cells/μL, elevated and
extreme as >6000cells/μL. At the phylum level, the
microbiome was dominated by Proteobacteria and Fir-
micutes, corresponding to dominant genera of Hae-
mophilus (n = 59 patients) and Streptococcus (n = 78) at
the genus level (e-Figure 11). Additional dominant gen-
era observed included: Veillonella (n = 55), Neisseria
(n = 12), Pseudomonas (n = 11), Moraxella (n = 8) and
Prevotella (n = 7). The BNC count of the samples was
significantly associated with increased % Proteobacteria
(P = 0.027) and reduced Shannon Wiener Diversity Index
(P = 0.0017) (Fig. 4 a and b). Beta diversity was assessed
using the Bray Curtis Dissimilarity Index and Weighted
UNIFRAC (Fig. 4c). Between patients, the microbiome
composition was shown to be significantly different by
PERMANOVA when comparing patients with BNCs <
6000cells/μL to patients with BNCs >6000cells/μL (P =
0.014), which remained statistically significant (P =
0.021) when adjusted for age, sex and smoking status
(Fig. 4d).
ECLIPSE validation cohort
The observation that BNC was associated with mortality
in COPD was confirmed in the ECLIPSE cohort. From
2164 COPD patients enrolled in ECLIPSE, 1934 partici-
pants were alive at the end of the original 3 year study
period. One thousand five hundred fifty-five participants
consented to an assessment of survival at 8 years; the
379 patients who did not participate in the 8 year sur-
vival assessment were censored. In the Cox proportional
hazards model adjusted for age, prior hospitalization and
BODE index, BNC was independently associated with
decreased survival as a linear variable (HR 1.20 95%CI
1.11–1.29, P < 0.0001).
Discussion
This study shows that BNCs are strongly related to long
term mortality in COPD and to the frequency of exacer-
bations and hospitalizations. Patients with BNCs
>6000cells/μL had markedly poorer outcomes regardless
Fig. 3 a: Kaplan Meier survival curves, with 95% confidence intervals, showing all-cause mortality for the normal (black) and elevated (red) BNC
groups adjusted for age, sex, and smoking status. b: As A, but representing mortality recorded as ICD10 J44, with all other mortality as a
competing risk. c: Ratios of the numbers of all, and severe, exacerbations over the year from the index date from both unadjusted models and
models adjusted for age, sex and smoking status. All are relative to the normal BNC group. d: Rates of change of FEV1, estimated by fitting mixed
models to either all data or only that obtained in the three years from each individual’s index date. For clarity, the low and extreme BNC groups
are not shown here, though equivalent plots showing all four BNC groups are shown in supplementary e-Figure 6
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of the time point in their COPD disease course that the
BNC was measured. We evaluated BNCs 12months
after initial enrolment into the TARDIS, which would be
close to diagnosis for many patients, and the penultimate
BNC in the study which was later in the disease course;
in both cases BNC was strongly and independently asso-
ciated with poor outcomes. Obtaining a similar result at
two different time points represents a degree of internal
validation and the finding was externally validated in the
ECLIPSE cohort. In ECLIPSE, increasing BNC was
clearly associated with increased mortality even after ad-
justment for the BODE index. In the TARDIS cohort,
both all causes and respiratory mortality were increased,
and this is consistent with the knowledge that systemic
inflammation contributes to both respiratory morbidity
and co-morbidities, which are a major feature of COPD
[12, 13].
We extended our findings by demonstrating a statisti-
cally significant difference in the microbiome between
patients with different stable BNCs. Patients with higher
blood neutrophil counts had a lower microbiota diver-
sity, a parameter known to be associated with more se-
vere COPD and a higher frequency of exacerbations, and
also had a higher relative abundance of Proteobacteria
[14]. This phylum includes the pathogenic genera Hae-
mophilus, Moraxella and Pseudomonas which are linked
to lung neutrophilic inflammation and poorer clinical
outcomes [15]. It is not possible to determine whether
differences in the microbiome are directly causing in-
creased blood neutrophil counts or if both are a reflec-
tion of a separate process.
The main role of neutrophils is to kill bacteria, princi-
pally through phagocytosis. Neutrophils migrate from
the peripheral blood circulation towards inflammatory
stimuli due to chemotactic factors, becoming activated
and releasing NE as they migrate through the extracellu-
lar matrix [2]. Killing of bacteria is achieved either
through phagocytosis, by releasing reactive oxygen spe-
cies (ROS), lactoferrin and proteinases, or by producing
NETs [3, 16]. However, in COPD, despite the presence
Fig. 4 Comparisons of BNCs to a: percentage Proteobacteria in the microbiome from n = 246 stable COPD patients. b: SWDI, a measure of the
microbiome diversity. c: Bray Curtis dissimilarity index and Weighted UNIFRAC were used to assess the differences in the microbiome between
pairs of patients with the same BNC (<6000BNCs/μL or > 6000BNCs/μL) and between those pairs of patients with different BNCs (<6000BNCs/μL
v > 6000BNCs/μL). d: PCoA plot showing the relationship between samples according to BNC
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of large numbers of neutrophils in the lungs, disease
progression continues, driven by exacerbations which
are often infectious in nature [17].
It appears that the large numbers of neutrophils ob-
served both in the lungs and in systemic circulation are
defective in their innate immune function: Ex vivo stud-
ies have shown that neutrophils from COPD patients are
more activated; demonstrating increased levels of
chemotaxis but that the accuracy of the direction of
movement is impaired [18–20]. Milara et al, in a study
on peripheral blood neutrophils from early onset COPD
patients, showed the NE release was 2-fold greater and
ROS release was 30% greater compared to healthy con-
trols [18]. Jones et al compared COPD patients with or
without a frequent exacerbator phenotype; they observed
that bacterial stimulated neutrophil degranulation was
greater in the frequent exacerbator group, but that all
COPD derived blood neutrophils had a blunted fMLP
stimulated oxidative burst response compared to healthy
controls [21].
The effects of COPD are not restricted to the lungs; evi-
dence of persistent systemic inflammation has been
assessed by measuring white blood count, C-reactive pro-
tein, interleukins 6 and 8 or TNF-α in serum [8, 22]; 16%
of COPD patients in the ECLIPSE cohort were shown to
have markers of systemic inflammation present [23, 24].
Wouters et al showed systemic markers of inflammation
were upregulated during exacerbations [9, 25, 26]. Comor-
bidities (e.g. osteoporosis, hypertension, cardiovascular
disease or diabetes) are commonly present in COPD pa-
tients [12, 13], with more comorbidities being recorded in
patients with the most severe lung function restriction in
the ARIC and CHS studies [27]. In the BODE cohort,
COPD patients had an average of four co-morbidities [28],
with comorbidities being the primary cause of death in
60% of non-survivors in two random controlled trials [29].
Our study adds to this evidence that COPD patients have
persistent systemic inflammation and that this is linked to
poor clinical outcomes.
How might BNCs be useful in clinical assessment of
patients with COPD? Unlike blood eosinophil counts
there is not yet evidence that BNCs can help guide ther-
apy. Unfortunately, to date, there are few effective treat-
ments for neutrophilic inflammation since NE inhibitors,
CXCR2 antagonists and other neutrophil specific therap-
ies have not yet been shown to improve outcomes in
broad populations of COPD patients [30, 31]. Neverthe-
less, there is an established precedent for blood bio-
markers being used to guide treatment of inflammatory
endotypes, as in the case of blood eosinophil counts and
anti-IL-5 therapy. It is theoretically possible that BNCs
could serve a similar function for anti-neutrophil therap-
ies. In clinical practice it is helpful to identify patients at
higher risk of exacerbation or mortality in order to
intensify therapy or provide closer monitoring. One po-
tential biomarker that has been investigated is the
neutrophil-lymphocyte ratio (NLR), however, the move
from using relative to absolute eosinophil counts sug-
gests that a ratio could be harder to apply clinically
meaningful cutoffs to, whereas the use of BNC could be
easier to interpret than the NLR [32]. Our study, which
is an order of magnitude larger than the studies on NLR
in COPD [33], suggests that patients with an elevated
BNC when stable who do not have an obvious alterna-
tive cause of an increased BNC may be at higher risk of
COPD complications and therefore may require closer
observation.
Our study has important limitations. The TARDIS
study was retrospective and has the limitations of obser-
vational research. It is older than other similar cohorts
that have been examined, though neither adjusting the
models for age nor restricting the analysis to the youn-
ger individuals changed the results. We used ICD codes
for classification of mortality and these have well de-
scribed limitations of accuracy. Nevertheless, our sample
size and the consistency of our results across multiple
subanalyses suggest no important bias. The use of oral
corticosteroid prescription to identify exacerbations is
well established in COPD studies using electronic health
records but this approach has limitations. Our very large
sample size and the results of sensitivity analyses includ-
ing antibiotic prescriptions suggest exacerbation defin-
ition is unlikely to have had a major effect on the
results. Although we used a conservative strategy to
avoid capturing BNCs during acute infections, we were
not able to prospectively identify the underlying reasons
for elevated BNCs in these patients. The mechanistic
sub-cohort study is limited by a relatively small sample
size, despite being among the largest reported COPD
microbiome studies, and so replication of our results in
larger cohorts, other than ECLIPSE, would be valuable.
In summary, this large observational cohort study has
identified BNCs as a strong and consistent predictor of fu-
ture exacerbations and mortality in stable COPD. The neu-
trophil remains central to the pathophysiology of COPD
and therapeutic development targeting neutrophilic inflam-
mation in appropriate patients is urgently needed.
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